• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro activity of BRL 17421 against Haemophilus influenzae, Neisseria gonorrhoeae, and Branhamella catarrhalis.BRL 17421对流感嗜血杆菌、淋病奈瑟菌和卡他布兰汉菌的体外活性。
Antimicrob Agents Chemother. 1982 Jan;21(1):166-7. doi: 10.1128/AAC.21.1.166.
2
In vitro activity of amoxicillin plus clavulanic acid against Haemophilus influenzae and Branhamella catarrhalis.阿莫西林加克拉维酸对流感嗜血杆菌和卡他莫拉菌的体外活性。
Eur J Clin Microbiol. 1986 Dec;5(6):615-21. doi: 10.1007/BF02013284.
3
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.克拉维酸与CP-45,899：二者与青霉素联合应用的体外活性比较
J Antimicrob Chemother. 1980 Mar;6(2):197-206. doi: 10.1093/jac/6.2.197.
4
In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis.新型口服头孢菌素BAY v 3522针对流感嗜血杆菌和卡他布兰汉菌的体外活性
Diagn Microbiol Infect Dis. 1990 Jul-Aug;13(4):349-52. doi: 10.1016/0732-8893(90)90030-y.
5
Antibiotic susceptibility of beta-lactamase-producing strains of Branhamella (Neisseria) catarrhalis.产β-内酰胺酶的卡他布兰汉菌（奈瑟菌属）菌株的抗生素敏感性
Antimicrob Agents Chemother. 1980 Jan;17(1):24-9. doi: 10.1128/AAC.17.1.24.
6
Antibacterial activity of nine oral antibiotics against Streptococcus pneumoniae, Haemophilus influenzae and Branhamella catarrhalis.
Scand J Infect Dis Suppl. 1983;39:106-8.
7
Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae.低浓度克拉维酸对阿莫西林体外抗产β-内酰胺酶卡他莫拉菌和流感嗜血杆菌活性的影响。
J Antimicrob Chemother. 1990 Sep;26(3):371-80. doi: 10.1093/jac/26.3.371.
8
In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.头孢哌酮、头孢噻肟、拉氧头孢（LY127935）、阿洛西林、美洛西林及其他β-内酰胺类抗生素对淋病奈瑟菌和流感嗜血杆菌的体外抗菌活性，包括产β-内酰胺酶菌株。
Antimicrob Agents Chemother. 1980 Apr;17(4):757-61. doi: 10.1128/AAC.17.4.757.
9
In-vitro activity of amoxycillin/clavulanic acid and five other oral antibiotics against clinical isolates of Haemophilus influenzae and Branhamella catarrhalis.阿莫西林/克拉维酸及其他五种口服抗生素对流感嗜血杆菌和卡他布兰汉菌临床分离株的体外活性
J Antimicrob Chemother. 1988 Dec;22(6):867-72. doi: 10.1093/jac/22.6.867.
10
Evidence for a true post-beta-lactamase-inhibitor effect of clavulanic acid against Klebsiella pneumoniae and Haemophilus influenzae.
Clin Microbiol Infect. 2001 Dec;7(12):661-5. doi: 10.1046/j.1469-0691.2001.00336.x.

引用本文的文献

1
Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic.替莫西林：作为一种潜在的碳青霉烯类替代抗生素在抗菌药物管理中的应用。
Antibiotics (Basel). 2022 Apr 7;11(4):493. doi: 10.3390/antibiotics11040493.
2
In vitro activity of temocillin (BRL 17421), a novel beta-lactam antibiotic.新型β-内酰胺抗生素替莫西林（BRL 17421）的体外活性
Antimicrob Agents Chemother. 1982 Oct;22(4):535-40. doi: 10.1128/AAC.22.4.535.
3
Comparative in vitro and in vivo activity of temocillin (BRL 17421) and ampicillin against Haemophilus influenzae type b.替莫西林（BRL 17421）与氨苄西林对b型流感嗜血杆菌的体外和体内活性比较
Antimicrob Agents Chemother. 1983 Jan;23(1):182-4. doi: 10.1128/AAC.23.1.182.
4
Renal clearance of temocillin in volunteers.
Drugs. 1985;29 Suppl 5:128-34. doi: 10.2165/00003495-198500295-00027.
5
In vitro activity of temocillin against clinical isolates.
Drugs. 1985;29 Suppl 5:1-8. doi: 10.2165/00003495-198500295-00003.
6
Temocillin. In vitro activity compared with other antibiotics.
Drugs. 1985;29 Suppl 5:91-7. doi: 10.2165/00003495-198500295-00018.
7
Interpretive criteria for temocillin disk diffusion susceptibility testing.替莫西林纸片扩散法药敏试验的解释标准。
Eur J Clin Microbiol. 1985 Feb;4(1):30-3. doi: 10.1007/BF02148656.

本文引用的文献

1
BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.BRL 17421是一种新型β-内酰胺抗生素，对β-内酰胺酶具有高度抗性，在人体内可产生高且持久的血清浓度。
Antimicrob Agents Chemother. 1981 Jul;20(1):38-46. doi: 10.1128/AAC.20.1.38.
2
In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type b.阿莫西林与克拉维酸对耐氨苄西林的b型流感嗜血杆菌的体外及体内协同作用
Antimicrob Agents Chemother. 1981 Jun;19(6):993-6. doi: 10.1128/AAC.19.6.993.
3
Antibiotic susceptibility of Neisseria gonorrhoeae strains from Europe and Africa.来自欧洲和非洲的淋病奈瑟菌菌株的抗生素敏感性
Antimicrob Agents Chemother. 1979 Apr;15(4):535-9. doi: 10.1128/AAC.15.4.535.
4
Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis.细菌性脑膜炎患者脑脊液中的细菌浓度。
J Pediatr. 1976 Apr;88(4 Pt 1):549-52. doi: 10.1016/s0022-3476(76)80003-0.

BRL 17421对流感嗜血杆菌、淋病奈瑟菌和卡他布兰汉菌的体外活性。

In vitro activity of BRL 17421 against Haemophilus influenzae, Neisseria gonorrhoeae, and Branhamella catarrhalis.

作者信息

Piot P, Van Dyck E

出版信息

Antimicrob Agents Chemother. 1982 Jan;21(1):166-7. doi: 10.1128/AAC.21.1.166.

DOI:10.1128/AAC.21.1.166
PMID:6805422
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC181846/
Abstract

BRL 17421, a novel beta-lactam antibiotic, was tested in vitro against fastidious gram-negative bacteria and compared with amoxicillin and amoxicillin plus clavulanic acid. The compound showed good activity against Haemophilus influenzae (range of minimal inhibitory concentrations, 0.2 to 1 microgram/ml), Neisseria gonorrhoeae (0.007 to 0.5 microgram/ml), and Branhamella catarrhalis (0.03 to 0.1 microgram/ml). BRL 17421 exhibited excellent stability against the TEM-type beta-lactamase of H. influenzae and N. gonorrhoeae, and its activity was little affected by inoculum size. Minimal lethal concentrations of BRL 17421 for 10(7) colony-forming units of H. influenzae ranged between 0.5 and 4 micrograms/ml.

摘要

新型β-内酰胺抗生素BRL 17421针对苛养革兰氏阴性菌进行了体外测试，并与阿莫西林及阿莫西林加克拉维酸进行了比较。该化合物对流感嗜血杆菌（最低抑菌浓度范围为0.2至1微克/毫升）、淋病奈瑟菌（0.007至0.5微克/毫升）和卡他布兰汉菌（0.03至0.1微克/毫升）显示出良好活性。BRL 17421对流感嗜血杆菌和淋病奈瑟菌的TEM型β-内酰胺酶表现出优异的稳定性，其活性受接种量大小的影响很小。BRL 17421对10⁷个流感嗜血杆菌菌落形成单位的最低致死浓度在0.5至4微克/毫升之间。